Coverage: The Meridian legal market record (editorial).
Selected MENA markets only; no African country is named in the release text reviewed, so the African nexus is regional and is flagged accordingly.
| Record ID | TX-AFR-2026-0024 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Exclusive licence, In-licensing, Trade mark licence |
| IP rights | patent, know-how, trade mark |
| Status | Signed |
| Qualifying date | 2026-09-21 |
| Sector | Life sciences · Medical devices and wound care |
| African markets | Multi-jurisdictional |
| Licensed territory | Selected MENA markets; no list in the release. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- OMEZA Holdings Inc. (United States): licensor
- Hikma Pharmaceuticals (United Kingdom): licensee
Key terms
- Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: Selected MENA markets
Sources
- OMEZA Holdings Announces an Exclusive Licensing Agreement with Hikma in Select MENA Markets, OMEZA Holdings (via PRWeb), 2026-09-21
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


